NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

Oncolytics Biotech logo
$0.43 +0.05 (+13.20%)
Closing price 03:59 PM Eastern
Extended Trading
$0.44 +0.01 (+2.77%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Advanced

Key Stats

Today's Range
$0.38
▼
$0.44
50-Day Range
$0.34
▼
$0.81
52-Week Range
$0.33
▼
$1.30
Volume
1.74 million shs
Average Volume
1.26 million shs
Market Capitalization
$58.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Hold

Company Overview

Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer.

The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment.

Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions. The company’s work is focused on advancing pelareorep as a potential treatment for solid tumors.

AI Generated. May Contain Errors.

Oncolytics Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

ONCY MarketRank™: 
1.71667551779 of 5 stars

Oncolytics Biotech scored higher than 34% of companies evaluated by MarketBeat, and ranked 710th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncolytics Biotech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

  • Upside Potential

    Oncolytics Biotech has a consensus price target of $5.00, representing about 1,182.1% upside from its current price of $0.39.

  • Amount of Analyst Coverage

    Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oncolytics Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Oncolytics Biotech are expected to grow in the coming year, from ($0.29) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -1.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    6.94% of the float of Oncolytics Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncolytics Biotech has a short interest ratio ("days to cover") of 9.91.
  • Change versus previous month

    Short interest in Oncolytics Biotech has recently decreased by 3.83%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oncolytics Biotech does not currently pay a dividend.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • News Sentiment

    Oncolytics Biotech has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Oncolytics Biotech this week, compared to 3 articles on an average week.
  • Search Interest

    Only 3 people have searched for ONCY on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Oncolytics Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.68% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    6.82% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONCY Stock News Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Oncolytics Biotech (ONCY) Projected to Post Earnings on Wednesday
See More Headlines

ONCY Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at $0.8740 on January 1st, 2026. Since then, ONCY stock has decreased by 55.4% and is now trading at $0.39.

Oncolytics Biotech Inc. (NASDAQ:ONCY) released its quarterly earnings results on Friday, November, 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03.

Top institutional investors of Oncolytics Biotech include International Assets Investment Management LLC (0.35%) and Fifth Third Bancorp (0.07%). Insiders that own company stock include Bernd R Seizinger, Wayne Pisano, Kirk Look, Thomas Charles Heineman, Allison Hagerman, Jared Kelly, Deborah Margaret Brown, Patricia S Andrews, Andrew Aromando and James T Parsons.
View institutional ownership trends
.

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include NVIDIA (NVDA), NIO (NIO), Plug Power (PLUG), Sorrento Therapeutics (SRNE), Palantir Technologies (PLTR), Intel (INTC) and Nokia (NOK).

Company Calendar

Last Earnings
11/13/2026
Today
11/18/2026
AGM 2026
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ONCY
CIK
1129928
Employees
29
Year Founded
1998

Price Target and Rating

High Price Target
$5.00
Low Price Target
$5.00
Potential Upside/Downside
+1,116.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$28.76 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-477.70%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.35
Quick Ratio
1.35

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.04) per share
Price / Book
-10.28

Miscellaneous

Outstanding Shares
136,140,000
Free Float
124,985,000
Market Cap
$55.95 million
Optionable
Not Optionable
Beta
1.26

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:ONCY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners